EYE Stock Overview
Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nova Eye Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.15 |
| 52 Week High | AU$0.33 |
| 52 Week Low | AU$0.11 |
| Beta | 0.96 |
| 11 Month Change | -15.07% |
| 3 Month Change | -27.91% |
| 1 Year Change | -6.06% |
| 33 Year Change | -62.20% |
| 5 Year Change | -73.73% |
| Change since IPO | -55.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| EYE | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -11.4% | -0.6% | -1.1% |
| 1Y | -6.1% | 15.2% | 16.1% |
Return vs Industry: EYE underperformed the Australian Medical Equipment industry which returned 15.2% over the past year.
Return vs Market: EYE underperformed the Australian Market which returned 16.1% over the past year.
Price Volatility
| EYE volatility | |
|---|---|
| EYE Average Weekly Movement | 7.8% |
| Medical Equipment Industry Average Movement | 10.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: EYE has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: EYE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | n/a | Tom Spurling | www.nova-eye.com |
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter which offers malleability and manoeuvrability than common nylon alternatives; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020.
Nova Eye Medical Limited Fundamentals Summary
| EYE fundamental statistics | |
|---|---|
| Market cap | AU$35.50m |
| Earnings (TTM) | -AU$8.79m |
| Revenue (TTM) | AU$23.33m |
1.5x
P/S Ratio-4.0x
P/E RatioIs EYE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYE income statement (TTM) | |
|---|---|
| Revenue | AU$23.33m |
| Cost of Revenue | AU$3.13m |
| Gross Profit | AU$20.19m |
| Other Expenses | AU$28.98m |
| Earnings | -AU$8.79m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.038 |
| Gross Margin | 86.57% |
| Net Profit Margin | -37.68% |
| Debt/Equity Ratio | 0% |
How did EYE perform over the long term?
See historical performance and comparison